Home
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $423.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.06.2025 | Series D | $96.5M | - |
| 31.03.2022 | Series C | $100M | - |
| 02.03.2021 | Series A | $113.5M | - |
| 16.12.2020 | Series A | $113.5M | - |
Mentions in press and media 15
| Date | Title | Description |
| 25.06.2025 | Neuron23: Pioneering Precision Medicine with a $96.5 Million Boost | In the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici... |
| 25.06.2025 | Neuron23 Raises $96.5M in Series D Financing | Neuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding. The round wa sled by heal... |
| 24.06.2025 | Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological Medicines | Neuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar... |
| 04.04.2022 | Neuron23 Closes $100M Series C Financing | Neuron23, a South San Francisco, CA-based biotechnology company, raised $100M in Series C funding. The round, which brought total financing raised to date to $213.5m, was led by SoftBank Vision Fund 2, with participation from Westlake Villa... |
| 31.03.2022 | Neuron23 nabs $100M in SoftBank-led round | Neuron23 has raised a $100 million Series C led by SoftBank's Vision Fund 2. Based in the Bay Area, the company is developing precision medicines for genetically defined neurological and immunological diseases. View round |
| 30.03.2022 | Neuron23 Grabs $100M in Series C | SOUTH SAN FRANCISCO, CA, Neuron23, an early stage biotechnology company, has closed a $100 million Series C financing. >> Click here for more funding data on Neuron23 >> To export Neuron23 funding data to PDF and Excel, clic... |
| 30.03.2022 | Neuron23 snags $100M and a new Parkinson's disease candidate | Neuron23 has picked a Parkinson’s disease clinical candidate, and, now, the small neurodegenerative-disease-focused biotech will have $100 million more to work with. The young biotech has just completed a series C financing with plans for a... |
| 02.03.2021 | Neuron23 closes USD 113.5 million series A and B financing | Martinsried-based Origenis GmbH has announced the formation and funding of South San Francisco biotech company Neuron23 Inc. Neuron23 was launched through a partnership with biotechnology company Origenis with venture capitalist Kleiner Per... |
| 17.12.2020 | Neuron23 emerges from stealth with $113.5M | Neuron23 has announced $33.5 million in Series A funding from WestLake Village BioPartners and Kleiner Perkins, and $80 million in a round led by Redmile Group, with participation from investors including Westlake, Kleiner Perkins, Cowen He... |
| 16.12.2020 | Neuron23 Snags $113.5M in Series A and B | SOUTH SAN FRANCISCO, CA, Neuron23 today announced its launch backed by a combined $113.5 million Series A and B financing. >> Click here for more funding data on Neuron23 >> To export Neuron23 funding data to PDF and Excel, ... |
Show more